环丙酚联合舒芬太尼抑制年轻和老年患者喉罩气道插入反应的中位有效剂量。

IF 2.3 3区 医学 Q2 ANESTHESIOLOGY
Xuelei Zhou, Li Zhao, Wei Mao, Linlin Chen, Xianchun Liu, Linji Li
{"title":"环丙酚联合舒芬太尼抑制年轻和老年患者喉罩气道插入反应的中位有效剂量。","authors":"Xuelei Zhou, Li Zhao, Wei Mao, Linlin Chen, Xianchun Liu, Linji Li","doi":"10.1186/s12871-024-02855-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Ciprofol, a novel intravenous anesthetic, exhibits similar sedation mechanisms and pharmacokinetic properties to propofol. However, ciprofol demonstrates greater potency and is associated with reduced injection pain compared to propofol. Given the varying sensitivities to anesthetic agents across different age groups, this study aims to determine the median effective dose (ED<sub>50</sub>) of ciprofol required to suppress the laryngeal mask airway (LMA) insertion response in both young and older adult patients, as well as to assess its potential adverse reactions.</p><p><strong>Methods: </strong>In this study, 46 patients scheduled for surgery under general anesthesia with LMA insertion were recruited. Upon entering the operating room, patients were intravenously administered ciprofol (0.4 mg·kg<sup>- 1</sup>) and sufentanil (0.3 µg·kg<sup>- 1</sup>), followed by LMA insertion after three minutes. To derive robust confidence intervals for both ED<sub>50</sub> and ED<sub>95</sub>, we performed an analysis using a logistic regression model combined with bootstrap resampling.</p><p><strong>Results: </strong>In the young adult group, the ED<sub>50</sub> and ED<sub>95</sub> of ciprofol for suppressing the LMA insertion response were 0.38 mg·kg<sup>- 1</sup> (95% CI, 0.35-0.41) and 0.46 mg·kg<sup>- 1</sup> (95%CI, 0.40-0.56), respectively. In the older adult group, the respective ED<sub>50</sub> and ED<sub>95</sub> were 0.29 mg·kg<sup>- 1</sup> (95% CI, 0.26-0.32) and 0.37 mg·kg<sup>- 1</sup> (95% CI, 0.30-0.78). Regarding adverse reactions, although there were differences in the incidence of injection pain, hypotension, and bradycardia between the young and older groups, no statistically significant differences were observed between the two groups.</p><p><strong>Conclusion: </strong>In this study, significant differences were observed in the ED<sub>50</sub> of ciprofol for suppressing the LMA insertion response between young and older adult patients. The ED<sub>50</sub> of ciprofol for young adult patients was 0.38 mg·kg<sup>- 1</sup> (95% CI, 0.35-0.41), while for older adult patients it was0.29 mg·kg<sup>- 1</sup> (95% CI, 0.26-0.32).</p><p><strong>Trial registration: </strong>This study was registered on February 17, 2024, with the China Clinical Trial Registration Center ( www.chictr.org.cn ; Registration Number: ChiCTR2400080891).</p>","PeriodicalId":9190,"journal":{"name":"BMC Anesthesiology","volume":"24 1","pages":"464"},"PeriodicalIF":2.3000,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The median effective dose of ciprofol combined with sufentanil in suppressing the laryngeal mask airway insertion response in both young and older adult patients.\",\"authors\":\"Xuelei Zhou, Li Zhao, Wei Mao, Linlin Chen, Xianchun Liu, Linji Li\",\"doi\":\"10.1186/s12871-024-02855-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Ciprofol, a novel intravenous anesthetic, exhibits similar sedation mechanisms and pharmacokinetic properties to propofol. However, ciprofol demonstrates greater potency and is associated with reduced injection pain compared to propofol. Given the varying sensitivities to anesthetic agents across different age groups, this study aims to determine the median effective dose (ED<sub>50</sub>) of ciprofol required to suppress the laryngeal mask airway (LMA) insertion response in both young and older adult patients, as well as to assess its potential adverse reactions.</p><p><strong>Methods: </strong>In this study, 46 patients scheduled for surgery under general anesthesia with LMA insertion were recruited. Upon entering the operating room, patients were intravenously administered ciprofol (0.4 mg·kg<sup>- 1</sup>) and sufentanil (0.3 µg·kg<sup>- 1</sup>), followed by LMA insertion after three minutes. To derive robust confidence intervals for both ED<sub>50</sub> and ED<sub>95</sub>, we performed an analysis using a logistic regression model combined with bootstrap resampling.</p><p><strong>Results: </strong>In the young adult group, the ED<sub>50</sub> and ED<sub>95</sub> of ciprofol for suppressing the LMA insertion response were 0.38 mg·kg<sup>- 1</sup> (95% CI, 0.35-0.41) and 0.46 mg·kg<sup>- 1</sup> (95%CI, 0.40-0.56), respectively. In the older adult group, the respective ED<sub>50</sub> and ED<sub>95</sub> were 0.29 mg·kg<sup>- 1</sup> (95% CI, 0.26-0.32) and 0.37 mg·kg<sup>- 1</sup> (95% CI, 0.30-0.78). Regarding adverse reactions, although there were differences in the incidence of injection pain, hypotension, and bradycardia between the young and older groups, no statistically significant differences were observed between the two groups.</p><p><strong>Conclusion: </strong>In this study, significant differences were observed in the ED<sub>50</sub> of ciprofol for suppressing the LMA insertion response between young and older adult patients. The ED<sub>50</sub> of ciprofol for young adult patients was 0.38 mg·kg<sup>- 1</sup> (95% CI, 0.35-0.41), while for older adult patients it was0.29 mg·kg<sup>- 1</sup> (95% CI, 0.26-0.32).</p><p><strong>Trial registration: </strong>This study was registered on February 17, 2024, with the China Clinical Trial Registration Center ( www.chictr.org.cn ; Registration Number: ChiCTR2400080891).</p>\",\"PeriodicalId\":9190,\"journal\":{\"name\":\"BMC Anesthesiology\",\"volume\":\"24 1\",\"pages\":\"464\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-12-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Anesthesiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12871-024-02855-5\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ANESTHESIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Anesthesiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12871-024-02855-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

本文章由计算机程序翻译,如有差异,请以英文原文为准。
The median effective dose of ciprofol combined with sufentanil in suppressing the laryngeal mask airway insertion response in both young and older adult patients.

Background: Ciprofol, a novel intravenous anesthetic, exhibits similar sedation mechanisms and pharmacokinetic properties to propofol. However, ciprofol demonstrates greater potency and is associated with reduced injection pain compared to propofol. Given the varying sensitivities to anesthetic agents across different age groups, this study aims to determine the median effective dose (ED50) of ciprofol required to suppress the laryngeal mask airway (LMA) insertion response in both young and older adult patients, as well as to assess its potential adverse reactions.

Methods: In this study, 46 patients scheduled for surgery under general anesthesia with LMA insertion were recruited. Upon entering the operating room, patients were intravenously administered ciprofol (0.4 mg·kg- 1) and sufentanil (0.3 µg·kg- 1), followed by LMA insertion after three minutes. To derive robust confidence intervals for both ED50 and ED95, we performed an analysis using a logistic regression model combined with bootstrap resampling.

Results: In the young adult group, the ED50 and ED95 of ciprofol for suppressing the LMA insertion response were 0.38 mg·kg- 1 (95% CI, 0.35-0.41) and 0.46 mg·kg- 1 (95%CI, 0.40-0.56), respectively. In the older adult group, the respective ED50 and ED95 were 0.29 mg·kg- 1 (95% CI, 0.26-0.32) and 0.37 mg·kg- 1 (95% CI, 0.30-0.78). Regarding adverse reactions, although there were differences in the incidence of injection pain, hypotension, and bradycardia between the young and older groups, no statistically significant differences were observed between the two groups.

Conclusion: In this study, significant differences were observed in the ED50 of ciprofol for suppressing the LMA insertion response between young and older adult patients. The ED50 of ciprofol for young adult patients was 0.38 mg·kg- 1 (95% CI, 0.35-0.41), while for older adult patients it was0.29 mg·kg- 1 (95% CI, 0.26-0.32).

Trial registration: This study was registered on February 17, 2024, with the China Clinical Trial Registration Center ( www.chictr.org.cn ; Registration Number: ChiCTR2400080891).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
BMC Anesthesiology
BMC Anesthesiology ANESTHESIOLOGY-
CiteScore
3.50
自引率
4.50%
发文量
349
审稿时长
>12 weeks
期刊介绍: BMC Anesthesiology is an open access, peer-reviewed journal that considers articles on all aspects of anesthesiology, critical care, perioperative care and pain management, including clinical and experimental research into anesthetic mechanisms, administration and efficacy, technology and monitoring, and associated economic issues.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信